Compare SPXC & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPXC | MEDP |
|---|---|---|
| Founded | 1912 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 11.7B |
| IPO Year | 1994 | 2016 |
| Metric | SPXC | MEDP |
|---|---|---|
| Price | $208.20 | $422.94 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 12 |
| Target Price | $245.56 | ★ $473.17 |
| AVG Volume (30 Days) | 435.2K | ★ 448.2K |
| Earning Date | 04-30-2026 | 04-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 18.08 | ★ 20.98 |
| EPS | 1.19 | ★ 4.28 |
| Revenue | ★ $2,265,100,000.00 | N/A |
| Revenue This Year | $16.07 | $13.19 |
| Revenue Next Year | $7.68 | $7.75 |
| P/E Ratio | $167.78 | ★ $96.89 |
| Revenue Growth | ★ 14.17 | N/A |
| 52 Week Low | $147.39 | $284.48 |
| 52 Week High | $246.68 | $628.92 |
| Indicator | SPXC | MEDP |
|---|---|---|
| Relative Strength Index (RSI) | 45.52 | 39.22 |
| Support Level | $201.97 | $382.68 |
| Resistance Level | $209.38 | $485.13 |
| Average True Range (ATR) | 8.54 | 16.95 |
| MACD | -1.95 | -6.68 |
| Stochastic Oscillator | 28.96 | 32.15 |
SPX Technologies Inc supplies engineered heating, ventilation, and air conditioning, or HVAC, products, as well as detection and measurement technologies and power equipment. The company operates through two reportable segments. The HVAC segment which generates the majority of the revenue for the company, designs, manufactures, installs, and services cooling products, as well as heating and ventilation products. The Detection and Measurement technologies segment designs, manufactures, and installs underground pipe and cable locators and inspection equipment, bus-fare collection systems, and others. Geographically, the company has its operations in the United States, Canada, China, the United Kingdom, and Others. It derives maximum revenue from United States.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.